Innovation and e-health: 3 questions to Guillaume Leroy, Country Chair France

Guillaume Leroy, Sanofi
SHARE
Facebook
Linkedin

1. What does innovation mean for Sanofi?

 

Working hand in hand with patients, the best researchers in the world and the best companies and startups to build strong partnerships is essential for Sanofi. This open innovation approach can be found at every level of our organization: from R&D to production, from digital services to healthcare professionals and patients. In terms of e-health, open innovation is already firmly rooted in our strategy and Sanofi in France is fully involved in establishing solid relationships in the e-health ecosystem.

In this context, we will be present as a healthcare partner of Vivatech, a major event in the area of digital innovation and a great opportunity for Sanofi. Our ambition is to find the best ideas through contacts with promising startups. Big data, artificial intelligence, robotics and the “Internet of things”… Digital technologies are of great interest and we are convinced that it will be together that we will build the health of tomorrow.

 

2. How does it benefit your patients specifically?

 

The core of our mission is to respond to the needs of patients with one objective: to enable them to live healthier lives. We transform science into innovative health solutions on a daily basis.

In e-health, we are only at the beginning, but the potential is enormous. In France, we already offer e-solutions in our areas of expertise, such as cardiovascular diseases, rare diseases and pain management. In diabetes, Sanofi has developed several mobile applications as well as a telemedicine solution that has received a positive opinion for reimbursement in France.

For the next few years, we have decided to focus our e-health strategy in France on five essential shared needs: the connecting role of the dispensing pharmacist, who is the interface between the patient, the medicine and healthcare professionals, pharmacovigilance, diagnosis of skin disorders, diagnostic exploration in rare diseases, and vaccines. To develop relevant e-solutions, we will rely on the most adapted digital technologies: connected objects, collaborative and interactive platforms, big data, artificial intelligence, block chains, serious games and others.

 

“In e-health, we are only at the beginning, but the potential is enormous. In France, we already offer e-solutions in our areas of expertise, such as cardiovascular diseases, rare diseases and pain management.”

Guillaume Leroy, Country Chair France

 

3. You have just announced the creation of a laboratory entirely dedicated to e-health. What will it consist of?

 

At the end of 2017, we will open the 39BIS, which will be the first laboratory 100% dedicated to e-health and a first in France. With the 39BIS, we want to offer employees of Sanofi and all e-health players in France a place of openness and exchange dedicated to e-health. It will be located on the French “Sanofi Val de Bièvre” campus in Gentilly, near Paris. With this location, we will be able to anchor Sanofi’s digital strategy and interact increasingly with the ecosystem, including startups, schools, incubators and large companies. The 39BIS will offer a scalable offer of services and training to accelerate our ambitions in e-health. It is an important new step in our strong commitment to digital health!

Choose the topics that interest you, like:
or